Protagonist Therapeutics

$27.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$3.18 (+13.49%) Today

+$0.44 (+1.64%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell PTGX and other stocks, options, and ETFs commission-free!

About PTGX

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. The listed name for PTGX is Protagonist Therapeutics, Inc. Common Stock.

CEO

Dinesh V. Patel

Employees

Headquarters

Newark, California

Founded

2006

Market Cap

1.21B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

392.40K

High Today

$26.87

Low Today

$24.01

Open Price

$24.01

Volume

518.70K

52 Week High

$27.24

52 Week Low

$5.30

PTGX Earnings

-$1.18

-$0.79

-$0.39

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 16, After Hours